STOCK TITAN

CALCIMEDICA INC - CALC STOCK NEWS

Welcome to our dedicated page for CALCIMEDICA news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CALCIMEDICA stock.

Overview

CalciMedica Inc (CALC) is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel small molecule therapies that target calcium release-activated calcium (CRAC) channels. By focusing on CRAC channel inhibition, the company aims to modulate the immune response and protect against tissue injury in life-threatening inflammatory and immunologic diseases. Core therapeutic areas include autoimmune disorders, organ transplant rejection, acute pancreatitis with systemic inflammatory response syndrome (SIRS), acute kidney injury (AKI) with associated respiratory failure, and pediatric conditions linked to asparaginase-induced pancreatic toxicity.

Innovative Technology and Therapeutic Focus

At the heart of CalciMedica’s approach is its proprietary technology targeting CRAC channels. These channels play a critical role in cellular calcium influx and immune cell activation, which are central to the pathogenesis of numerous inflammatory and immunologic diseases. By selectively inhibiting CRAC channels, CalciMedica’s lead product candidate, Auxora™, is designed to attenuate overactive immune responses while simultaneously offering organ tissue protection. This dual mechanism of action underlines the potential of their therapies to treat conditions with high unmet medical need for which no approved therapies exist.

Clinical Programs and Pipeline

CalciMedica’s pipeline is robust, encompassing multiple clinical trials addressing severe acute illnesses:

  • Acute Pancreatitis (AP) with SIRS: The Phase 2b CARPO trial evaluates the efficacy of Auxora in improving clinical outcomes in AP patients. The trial is international, randomized, and placebo-controlled, ensuring rigorous assessment of dose-response and safety.
  • Acute Kidney Injury (AKI) with Respiratory Failure: The Phase 2 KOURAGE trial examines Auxora in patients with Stage 2 and Stage 3 AKI accompanied by acute hypoxemic respiratory failure. Enrollment criteria are designed to select patients experiencing severe inflammation, addressing a critical area with no current approved therapy.
  • Pediatric Asparaginase-Induced Pancreatic Toxicity (AIPT): An investigator-sponsored Phase 1/2 trial investigates Auxora’s potential in pediatric patients undergoing treatment for acute lymphoblastic leukemia, where asparaginase therapy can lead to debilitating pancreatic toxicity.

Market Position and Competitive Landscape

Within the dynamic biopharmaceutical landscape, CalciMedica differentiates itself through its focused approach on CRAC channel inhibition—a mechanism that directly addresses underlying inflammatory pathways rather than merely treating symptoms. The company has garnered attention from leading life science investors and secured strategic financing arrangements, highlighting confidence in its science and clinical promise. Its rigorous clinical trials and adherence to robust regulatory standards position it as a notable player in treating diseases with significant unmet needs.

Expertise, Safety, and Future Readiness

CalciMedica’s commitment to advancing therapies through well-designed clinical trials reinforces its expertise and credibility. Clinical data have consistently demonstrated a well-tolerated safety profile for Auxora™, with meaningful improvements in critical endpoints such as time to solid food tolerance in AP and reduction in severe organ failure in trial participants. Detailed and transparent reporting reinforces the company’s authoritativeness in its field while ensuring that the scientific community and investors receive balanced, factual information regarding its progress. The company’s strategy underlines its focus on solving complex inflammatory conditions through targeted and innovative approaches, reflecting deep industry insights and technical precision.

Summary

In summary, CalciMedica Inc is firmly positioned at the intersection of cutting-edge science and clinical need. Through its unique CRAC channel inhibition strategy, the company is addressing severe inflammatory and immunologic diseases with no current approved therapeutic options. With a clearly articulated clinical pipeline, robust scientific rationale, and considerable industry expertise, CalciMedica provides a comprehensive model of innovation and excellence in biopharmaceutical research and development.

Rhea-AI Summary
CalciMedica Inc. announced the participation of CEO Rachel Leheny in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company is focused on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses. The presentation will be available via live webcast and archived for 90 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.99%
Tags
conferences
-
Rhea-AI Summary
CalciMedica, Inc. announced a securities purchase agreement to raise up to $55 million in gross proceeds, with an upfront funding of $20.4 million and potential additional funding of $34.2 million. The financing will support the expansion of Auxora™ clinical development, including planned Phase 2 acute kidney injury (AKI) trial, and fund subsequent clinical trials in acute pancreatitis (AP) and AKI programs. New and existing investors, including healthcare-dedicated investors, are participating in the financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
none
-
Rhea-AI Summary
CalciMedica Inc. (CALC) announced positive results from the Phase 1/2 CRSPA study of Auxora™ in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition. Auxora treatment potentially reduces the severity of AIPT, eliminating the need for total parenteral nutrition, and resulting in reduced hospital and intensive care unit days. The study showed a 53% reduction in days in hospital and a 40% reduction in intensive care unit days compared to a historical matched control group. None of the Auxora-treated patients had significant necrosis compared to 27% of historical control patients at 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.88%
Tags
none
Rhea-AI Summary
CalciMedica Inc. (CALC) reported financial results and clinical updates for the third quarter, highlighting the expansion of Phase 1/2 CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT) and the international expansion of Phase 2b CARPO trial in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS). The company anticipates topline data from the CARPO trial in the first half of 2024 and is preparing to file an IND application for Auxora™ in acute kidney injury (AKI).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.74%
Tags
-
Rhea-AI Summary
CalciMedica Inc. announced the presentation of data from the CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT) at the ASH Meeting. The results showed a 53% reduction in hospital days, a 40% reduction in ICU days, and eliminated the need for total parenteral nutrition (TPN).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
none
-
Rhea-AI Summary
CalciMedica to participate in H.C. Wainwright conference and host virtual Acute Pancreatitis event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.18%
Tags
conferences
Rhea-AI Summary
CalciMedica to host virtual clinical experts event on September 21, 2023, discussing lead clinical compound Auxora™ and its potential implications in acute pancreatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
Rhea-AI Summary
CalciMedica reports financial results for Q2 2023 and provides updates on clinical trials and key leadership appointments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.07%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none

FAQ

What is the current stock price of CALCIMEDICA (CALC)?

The current stock price of CALCIMEDICA (CALC) is $1.83 as of April 3, 2025.

What is the market cap of CALCIMEDICA (CALC)?

The market cap of CALCIMEDICA (CALC) is approximately 24.9M.

What is the primary focus of CalciMedica Inc?

CalciMedica Inc focuses on developing novel small molecule therapies that inhibit CRAC channels to treat life-threatening inflammatory and immunologic diseases.

Which therapeutic areas are targeted by CalciMedica's pipeline?

The company's pipeline targets acute pancreatitis with SIRS, acute kidney injury with associated respiratory failure, and pediatric asparaginase-induced pancreatic toxicity.

How does CalciMedica's technology work?

CalciMedica's proprietary technology targets and inhibits CRAC channels to modulate immune responses and protect against tissue cell injury, addressing the underlying inflammation in various diseases.

What distinguishes Auxora™ from other drug candidates?

Auxora™ is distinguished by its dual mechanism of immunomodulation and direct tissue protection, offering potential therapeutic benefits in conditions with high unmet medical needs where no approved therapies exist.

Why is CRAC channel inhibition important in treating inflammatory diseases?

CRAC channels regulate calcium influx, which is pivotal in immune cell activation and inflammatory responses. Targeting these channels can help attenuate excessive inflammation and prevent cell injury.

What type of clinical trials is CalciMedica conducting?

CalciMedica is conducting multiple clinical trials, including randomized, placebo-controlled Phase 2b and Phase 2 studies in acute pancreatitis and acute kidney injury, as well as an investigator-sponsored Phase 1/2 trial in pediatric patients.

How is CalciMedica positioned within its competitive landscape?

CalciMedica differentiates itself with a focused approach on CRAC channel inhibition, supported by robust clinical data and strategic financing, positioning it as a specialized and credible player in the biopharmaceutical sector.
CALCIMEDICA INC

Nasdaq:CALC

CALC Rankings

CALC Stock Data

24.94M
11.10M
17.6%
52.45%
0.72%
Biotechnology
Pharmaceutical Preparations
Link
United States
LA JOLLA